Yunus Emre Kum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunus Emre Kum has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Ozge Pamukcu
Pediatric Cardiology, Erciyes University Medical Faculty, Kayseri, Turkey
5 shared publications - Ali Baykan
Department of Pediatrics, Division of Pediatric Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
4 shared publications - Alper Dogan
Pediatric Cardiology, Erciyes University Medical Faculty, Kayseri, Turkey
4 shared publications Ali Baykan
Department of Pediatric Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
3 shared publicationsAbdullah Ozyurt
Pediatric Cardiology, Mersin Women’s and Children’s Hospital, Mersin, Turkey
2 shared publications- Cem Karadeniz
Department of Pediatric Cardiology & Pediatric Arrhythmia & Electrophysiology Izmir Katip Celebi University Izmir Turkey
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Cardiology Research and Practice
- Vol. 2026 (1)
Comparison of Sizing Methods to Optimize Device Selection for Percutaneous Closure of Atrial Septal Defects
Background and Aims: Accurate sizing of atrial septal defects (ASDs) is crucial for appropriate device selection during percutaneous transcatheter closure. Despite the availability of multiple imaging and sizing techniques, no consensus exists on the optimal method for determining device size. This study aimed to compare preprocedural ASD measurements obtained using different techniques with the final device waist diameter and to identify the measurement method demonstrating the most favorable agreement and reproducibility. Methods: This retrospective study included 149 pediatric patients (64 males, 85 females) who underwent percutaneous transcatheter ASD closure. Preprocedural defect sizing was performed using transthoracic echocardiography (TTE), balloon sizing, and transesophageal echocardiography (TEE). TEE measurements were obtained in the four‐chamber, aortic, and bicaval views. In addition to individual diameters, the arithmetic mean, cube root–derived diameter, and maximal TEE‐measured diameter were calculated and compared with the final device waist diameter. The final device waist diameter, measured fluoroscopically after deployment, was used as the reference comparator, reflecting operator‐selected device sizing rather than true anatomical defect dimensions. Results: Among TEE‐based measurements, both the cube root–derived diameter and the arithmetic mean of TEE measurements demonstrated high reproducibility and favorable agreement with the final device waist diameter, with only marginal numerical differences between the two methods. Bland–Altman analysis supported these findings by showing minimal bias and narrow limits of agreement, whereas TTE and balloon sizing demonstrated lower, though statistically significant, concordance with the final device waist diameter. Conclusion: Combining multiple measurement techniques improves agreement with the operator‐selected device size during percutaneous ASD closure. While TTE alone may be sufficient in patients with simple defects and adequate acoustic windows, integrated approaches incorporating TEE and multiaxis measurements showed favorable agreement characteristics, particularly in anatomically heterogeneous defects or resource‐limited settings. These findings should be interpreted as reflecting agreement with operator‐selected device sizing rather than anatomical sizing accuracy, given the inherent circularity of using implanted device size as a reference standard.
- 1 January 2026
- Published by Wiley in Cardiology Research and Practice
- Vol. 2026 (1)
Open AccessComparison of Sizing Methods to Optimize Device Selection for Percutaneous Closure of Atrial Septal Defects
Background and Aims: Accurate sizing of atrial septal defects (ASDs) is crucial for appropriate device selection during percutaneous transcatheter closure. Despite the availability of multiple imaging and sizing techniques, no consensus exists on the optimal method for determining device size. This study aimed to compare preprocedural ASD measurements obtained using different techniques with the final device waist diameter and to identify the measurement method demonstrating the most favorable agreement and reproducibility. Methods: This retrospective study included 149 pediatric patients (64 males, 85 females) who underwent percutaneous transcatheter ASD closure. Preprocedural defect sizing was performed using transthoracic echocardiography (TTE), balloon sizing, and transesophageal echocardiography (TEE). TEE measurements were obtained in the four‐chamber, aortic, and bicaval views. In addition to individual diameters, the arithmetic mean, cube root–derived diameter, and maximal TEE‐measured diameter were calculated and compared with the final device waist diameter. The final device waist diameter, measured fluoroscopically after deployment, was used as the reference comparator, reflecting operator‐selected device sizing rather than true anatomical defect dimensions. Results: Among TEE‐based measurements, both the cube root–derived diameter and the arithmetic mean of TEE measurements demonstrated high reproducibility and favorable agreement with the final device waist diameter, with only marginal numerical differences between the two methods. Bland–Altman analysis supported these findings by showing minimal bias and narrow limits of agreement, whereas TTE and balloon sizing demonstrated lower, though statistically significant, concordance with the final device waist diameter. Conclusion: Combining multiple measurement techniques improves agreement with the operator‐selected device size during percutaneous ASD closure. While TTE alone may be sufficient in patients with simple defects and adequate acoustic windows, integrated approaches incorporating TEE and multiaxis measurements showed favorable agreement characteristics, particularly in anatomically heterogeneous defects or resource‐limited settings. These findings should be interpreted as reflecting agreement with operator‐selected device sizing rather than anatomical sizing accuracy, given the inherent circularity of using implanted device size as a reference standard.
- 27 May 2025
- Published by Academician Publishing
- p. 425-432
Konjenital Kalp Hastalıkları
- 27 May 2025
- Published by Academician Publishing
- p. 455-460
İnfektif Endokardit
- Open Access
- 27 May 2025
- Published by Academician Publishing
Canpolat-Karakükcü-Dursun-Poyrazoğlu Pediatride Temel Bilgiler
- 27 May 2025
- Published by Academician Publishing
Open AccessCanpolat-Karakükcü-Dursun-Poyrazoğlu Pediatride Temel Bilgiler
- 30 December 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 45 (2) , 282-291
One-Year Follow-Up Results of MIS-C Patients with Coronary Artery Involvement: A Multi-center Study
Multisystem inflammatory syndrome (MIS-C) in children is a rare complication of SARS-CoV-2 infection. Knowing the course of the affected or unaffected coronary arteries in the patients under follow-up is important in terms of defining the long-term prognosis of the disease and determining the follow-up plan. This is a multicenter and retrospective study. The data were obtained from nine different centers. Between May 2020 and August 2022, 68 of 790 patients had coronary artery involvement. One-year echocardiographic data of 67 of 789 MIS-C patients with coronary artery involvement were analyzed. Existing pathologies of the coronary arteries were grouped as increased echogenicity, dilatation and aneurysm according to Z scores, and their changes over a 1-year period were determined. The data of all three groups are defined as frequency. SPSS Statistics version 22 was used to evaluate the data. In our study, aneurysm was observed in 16.4%, dilatation in 68.7% and increased echogenicity in 13.4% of the patients. All of the patients with involvement in the form of increased echogenicity recovered without sequelae by the end of the first month. No progression to aneurysm was observed in any of the patients with dilatation. No new-onset involvement was observed in patients with previously healthy coronary arteries during the convalescent period. In addition, from the sixth month follow-up period, there was no worsening in the amount of dilatation in any of the patients. At least 94% of the patients who completed the 12th month control period returned to normal.
- 30 December 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 45 (2) , 282-291
One-Year Follow-Up Results of MIS-C Patients with Coronary Artery Involvement: A Multi-center Study
Multisystem inflammatory syndrome (MIS-C) in children is a rare complication of SARS-CoV-2 infection. Knowing the course of the affected or unaffected coronary arteries in the patients under follow-up is important in terms of defining the long-term prognosis of the disease and determining the follow-up plan. This is a multicenter and retrospective study. The data were obtained from nine different centers. Between May 2020 and August 2022, 68 of 790 patients had coronary artery involvement. One-year echocardiographic data of 67 of 789 MIS-C patients with coronary artery involvement were analyzed. Existing pathologies of the coronary arteries were grouped as increased echogenicity, dilatation and aneurysm according to Z scores, and their changes over a 1-year period were determined. The data of all three groups are defined as frequency. SPSS Statistics version 22 was used to evaluate the data. In our study, aneurysm was observed in 16.4%, dilatation in 68.7% and increased echogenicity in 13.4% of the patients. All of the patients with involvement in the form of increased echogenicity recovered without sequelae by the end of the first month. No progression to aneurysm was observed in any of the patients with dilatation. No new-onset involvement was observed in patients with previously healthy coronary arteries during the convalescent period. In addition, from the sixth month follow-up period, there was no worsening in the amount of dilatation in any of the patients. At least 94% of the patients who completed the 12th month control period returned to normal.
- Open Access
- 23 June 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (1) , 163
Piccolo in transcatheter PDA closure multicenter study from premature to adolescent children – CORRIGENDUM
- 23 June 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (1) , 163
Open AccessPiccolo in transcatheter PDA closure multicenter study from premature to adolescent children – CORRIGENDUM
- 7 June 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (1) , 157-162
Piccolo in transcatheter PDA closure multi-centre study from premature to adolescent children
In this multi-centre study, the mid- to long-term efficacy and safety of the Amplatzer Piccolo Occluder in patent ductus arteriosus closure in premature and term infants as well as children were discussed. Methods. Between 2016 and 2021, 645 patients, 152 of whom were less than 1 month old, underwent ductus closure with the Piccolo device from five different centres in Turkey. The median age of the patients was 2.2 years, and the mean narrowest point of duct diameter was 1.8 mm. Sixty-two patients weighed ≤ 1.5 kg, 90 patients 1.5–3 kg, and the mean follow-up was 20.4 months. In 396, the duct was closed by the retrograde route. Ductal anatomy was Type A in 285, C in 72, E in 171, and F in 64 patients. Fluoroscopy duration was 6.2 min. The procedure success rate was 99.1%. Device embolisation occurred in 13 patients (2%), and 11 were retrieved with a snare. Cardiac perforation and death developed in one premature baby. The left pulmonary artery and the descending aorta stenosis were observed in 3 (0.4%) and in 5 patients (0.5%). Results. Piccolo device is safe and effective in closing ductus in all age groups. It has low profile for use in premature and newborn babies, a small embolisation risk, and a low residual shunt rate after closure. Conclusion. The Piccolo device can be considered as close an ideal occluder. The lower profile, smaller delivery catheter size, and symmetry of this device allow for a venous or arterial approach.
- 7 June 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (1) , 157-162
Piccolo in transcatheter PDA closure multi-centre study from premature to adolescent children
In this multi-centre study, the mid- to long-term efficacy and safety of the Amplatzer Piccolo Occluder in patent ductus arteriosus closure in premature and term infants as well as children were discussed. Methods. Between 2016 and 2021, 645 patients, 152 of whom were less than 1 month old, underwent ductus closure with the Piccolo device from five different centres in Turkey. The median age of the patients was 2.2 years, and the mean narrowest point of duct diameter was 1.8 mm. Sixty-two patients weighed ≤ 1.5 kg, 90 patients 1.5–3 kg, and the mean follow-up was 20.4 months. In 396, the duct was closed by the retrograde route. Ductal anatomy was Type A in 285, C in 72, E in 171, and F in 64 patients. Fluoroscopy duration was 6.2 min. The procedure success rate was 99.1%. Device embolisation occurred in 13 patients (2%), and 11 were retrieved with a snare. Cardiac perforation and death developed in one premature baby. The left pulmonary artery and the descending aorta stenosis were observed in 3 (0.4%) and in 5 patients (0.5%). Results. Piccolo device is safe and effective in closing ductus in all age groups. It has low profile for use in premature and newborn babies, a small embolisation risk, and a low residual shunt rate after closure. Conclusion. The Piccolo device can be considered as close an ideal occluder. The lower profile, smaller delivery catheter size, and symmetry of this device allow for a venous or arterial approach.
- 12 May 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 33 (11) , 2384-2386
Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports
Multiple sclerosis is a chronic inflammatory and demyelinating disease of the central nervous system, usually seen in young adults. Early onset of multiple sclerosis at age younger than 18 years is called paediatric multiple sclerosis. Unlike adult multiple sclerosis, paediatric multiple sclerosis causes morbidity at earlier ages and often progresses in a relapsing–remitting form. Although fingolimod is an effective drug used as a disease-modifiying therapy agent in relapsing–remitting paediatric multiple sclerosis patients, it can cause dysryhthmia in the early period after first dose. Our first case is a 14-year-old girl with relapsing–remitting paediatric multiple sclerosis patients who was started to take fingolimod treatment. In the fifth hour of the follow-up, asymptomatic bradycardia was seen and the electrocardiogram was consistent with first-degree atrioventricular block. Her rhythm got spontaneously normal after 12 hours. Second case was 13 years old girl. Steroid treatment was started after her first paediatric multiple sclerosis attack. Despite treatment, she had a second attack 2 weeks after the first attack. Therefore, the neurologist switched to fingolimod therapy. Second-degree atrioventriculer block developed after 4 hours from the initiation of therapy. After 8 hours, rhythm regressed to first-degree atrioventricular block then returned to normal up to 13th hours of follow up. The aim of this article is to draw attention to dysrhythmia side effect of fingolimod which can be fatal. Therefore, the clinician must take precautions. Close cardiac rhythm monitoring is mandatory after the initiation fingolimod theraphy.
- 12 May 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 33 (11) , 2384-2386
Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports
Multiple sclerosis is a chronic inflammatory and demyelinating disease of the central nervous system, usually seen in young adults. Early onset of multiple sclerosis at age younger than 18 years is called paediatric multiple sclerosis. Unlike adult multiple sclerosis, paediatric multiple sclerosis causes morbidity at earlier ages and often progresses in a relapsing–remitting form. Although fingolimod is an effective drug used as a disease-modifiying therapy agent in relapsing–remitting paediatric multiple sclerosis patients, it can cause dysryhthmia in the early period after first dose. Our first case is a 14-year-old girl with relapsing–remitting paediatric multiple sclerosis patients who was started to take fingolimod treatment. In the fifth hour of the follow-up, asymptomatic bradycardia was seen and the electrocardiogram was consistent with first-degree atrioventricular block. Her rhythm got spontaneously normal after 12 hours. Second case was 13 years old girl. Steroid treatment was started after her first paediatric multiple sclerosis attack. Despite treatment, she had a second attack 2 weeks after the first attack. Therefore, the neurologist switched to fingolimod therapy. Second-degree atrioventriculer block developed after 4 hours from the initiation of therapy. After 8 hours, rhythm regressed to first-degree atrioventricular block then returned to normal up to 13th hours of follow up. The aim of this article is to draw attention to dysrhythmia side effect of fingolimod which can be fatal. Therefore, the clinician must take precautions. Close cardiac rhythm monitoring is mandatory after the initiation fingolimod theraphy.